MAP2K7 and acute myeloid leukemia: Other studies support the idea that combinations with MEK (35) or CDK9 (36–38) inhibitors could enhance venetoclax activity and circumvent resistance, and ongoing clinical studies in acute myeloid leukemia (AML) may soon provide clinical data (see below).